[Skip to content]

European Parkinson's Disease Association
Search our Site

MIRAPEXIN®/SIFROL® (pramipexole dihydrochloride)

This section provides a summary of the drug information for MIRAPEXIN® / SIFROL® (pramipexole). Information included in this section is not intended to be used as an alternative to consulting with a healthcare professional or other qualified professional. If you have any questions about your PD medication, or other aspects of your PD treatment, you should discuss these with your doctor or healthcare professional. It is always important that you read the full package leaflet that accompanies the product carefully before you start to take any medication.

Always check with your healthcare professional before altering any of your medications and always ask your pharmacist first if you are considering taking over-the counter medications as they can interfere with your Parkinson’s medications and may have unwanted side effects.  Remember to tell your doctor too if you take over-the counter drugs that can be bought without a prescription.

Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take this into account when referring to the information provided. For detailed information on the product safety, efficacy and tolerability profile, please refer to the country-specific summary of product characteristics/product information leaflet. This product information is not intended for dissemination within the U.S.A.

Boehringer Ingelheim

Information by courtesy, but not responsibility, of Boehringer Ingelheim International GmbH

Last reviewed April 2014

MIRAPEXIN® / SIFROL®  is registered as immediate release tablets and/or prolonged-release tablets in the following countries

MIRAPEXIN® (also known as SIFROL® in Europe) is a compound from Boehringer Ingelheim research first approved in 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEXIN® is used to treat the symptoms of primary Parkinson’s disease. In October 2009, MIRAPEXIN® was granted approval by the European Commission for a prolonged-release, once daily formulation in this indication. It can be used alone or in combination with levodopa.

In addition to its indication for the treatment of Parkinson’s disease, in 2006, MIRAPEXIN® (immediate release formulation) was approved for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

  • Albania

  • Argentina

  • Australia

  • Austria

  • Bahrain

  • Belarus

  • Belgium

  • Bolivia

  • Bosnia and Herzegovina

  • Botswana

  • Brazil

  • Bulgaria

  • Canada

  • Chile

  • China

  • Colombia

  • Croatia

  • Cuba
  • Cyprus

  • Czech Republic

  • Denmark

  • Ecuador

  • Egypt

  • El Salvador
  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Honduras


  • Hong Kong
  • Hungary
  • Iceland

  • Indonesia

  • Ireland

  • Israel

  • Italy

  • Japan

  • Jordan

  • Kazakhstan
  • Kenya

  • Korea

  • Kuwait

  • Latvia

  • Lebanon

  • Liechtenstein
  • Lithuania

  • Luxembourg

  • Macedonia

  • Malaysia

  • Malta

  • Mauritius

  • Mexico

  • Moldova
  • Montenegro

  • Morocco
  • Namibia

  • Netherlands

  • Nicaragua
  • Norway

  • Oman

  • Panama
  • Paraguay
  • Peru

  • Philippines

  • Qatar

  • Romania

  • Russian Federation

  • Saudi Arabia

  • Serbia

  • Singapore

  • Slovak Republic

  • Slovenia

  • South Africa

  • Spain

  • Swaziland

  • Sweden

  • Switzerland

  • Taiwan

  • Thailand

  • Tunisia
  • Turkey

  • UAE

  • UK

  • Ukraine

  • Uruguay
  • USA

  • Venezuela

  • Vietnam

Product Information Downloads

The information on this page is a general summary of the MIRAPEXIN®/ SIFROL®medication product.

Please click on the links below to access more detailed information on the MIRAPEXIN®/SIFROL® medication, its handling and use. Links go to the electronic Medicines Compendium (eMC) website

UK Patient Information Leaflets (PIL)

UK Summary of Product Characteristics (SPC)

Please note that SPCs are designed for healthcare professionals.

European Public Assessment Report

Links go to the The European Medicines Agency (EMA) website.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

For more information please visit www.boehringer-ingelheim.com.